
### [MONDO:0004600](http://purl.obolibrary.org/obo/MONDO_0004600)
**Label:** monocytic leukemia

**Subclasses:** [MONDO:0007896](http://purl.obolibrary.org/obo/MONDO_0007896) (acute monocytic leukemia), 

**Corr. equiv. classes:** [OMIM:151380](http://purl.obolibrary.org/obo/OMIM_151380), [Orphanet:514](http://www.orpha.net/ORDO/Orphanet_514), 

**Class expressions from DL-Learner:**

- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0004845](http://purl.obolibrary.org/obo/HP_0004845) (Acute monocytic leukemia) 75.00%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0002488](http://purl.obolibrary.org/obo/HP_0002488) (Acute leukemia) 75.00%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and (not ([HP:0005558](http://purl.obolibrary.org/obo/HP_0005558) (Chronic leukemia))) 75.00%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and (not ([HP:0005550](http://purl.obolibrary.org/obo/HP_0005550) (Chronic lymphatic leukemia))) 75.00%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0001909](http://purl.obolibrary.org/obo/HP_0001909) (Leukemia) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 60.36%
- [HP:0000118](http://purl.obolibrary.org/obo/HP_0000118) (Phenotypic abnormality) and [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) 60.36%
- [HP:0001444](http://purl.obolibrary.org/obo/HP_0001444) (Autosomal dominant somatic cell mutation) and [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 60.36%


